RxDoctor Payments Data

Jason Biehl, MD

Critical Care Medicine · Denver, CONPI 1538392311

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.1% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Intuitive Surgical at 40.5% of the total. Reporting peaked in 2023 at $385 and has fallen 52.9% since, to $182 in 2025.

$797in general payments, 2019–2025

Across 25 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$323
  • AstraZeneca$104
  • Regeneron Healthcare Solutions, Inc.$68
  • Sanofi$66
  • GSK$44
  • Insmed, Inc.$44
  • plus $149 from 6 others

What the payments were for

  • Food & beverage$78298%
  • Education$152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$797 in reported general payments places this provider in the 60th percentile of 141 critical care medicine providers in Colorado.

See all critical care medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$88,071
Medicare patients
245
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab12$46,560
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$45,499
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$12,336
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$11,092
DuleraMometasone/Formoterol21$8,840
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$4,593
Albuterol Sulfate HfaAlbuterol Sulfate15$584
Fluticasone Propionate11$316
Chlorhexidine Gluconate14$167
Prednisone31$136
Ciprofloxacin Hcl13$127

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$44$45,49949 claims
AstraZenecaBreztri Aerosphere$104$11,09212 claims
MerckDulera$25$8,84021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 141 critical care medicine providers in Colorado.

Other critical care medicine in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →